pharmaceuticals
- Repeal of LIFO (last in, first out) - Medicare prompt pay discount exclusion, including legislation to ensure appropriate reimbursement for drugs and biologics under Medicare Part B by excluding customary prompt-pay discounts extended to wholesalers from the manufacturer's Average Sales Price (ASP) (H.R. 1920); ASP, generally (in the context of Deficit Reduction).
- Legislation to exclude cancer drugs from sequestration cuts; Cancer Care Payment Reform Act (H.R. 1834/S. 463) - Legislation to prevent and reduce prescription drug abuse. Legislation to prohibit prescription drug plan sponsors and MA-PD organizations under Medicare from retroactively reducing payment on clean claims submitted by pharmacies. Pharmaceutical compounding and implementation of the Drug Quality Security Act. Issues related to drug pricing, including the Improving Access to Affordable Prescription Drug Act (H.R. 1776/S. 771).  Issues related to the importation of prescription medicines, including the Affordable and Safe Prescription Drug Importation Act (H.R. 1245/S. 469).
TAX - Taxation/Internal Revenue Code MMM - Medicare/Medicaid PHA - Pharmacy
2 - HOUSE OF REPRESENTATIVES 1 - SENATE 2 - HOUSE OF REPRESENTATIVES 1 - SENATE 2 - HOUSE OF REPRESENTATIVES 1 - SENATE
ROBERTI GLOBAL (F/K/A ROBERTI WHITE, LLC)
900 G Street NW, Suite 301, Washington, DC, 20001, US
STEVEN E IRIZARRY VINCENT A. ROBERTI, SR. ISRAEL S KLEIN STEVEN E IRIZARRY VINCENT A. ROBERTI, SR. ISRAEL S KLEIN STEVEN E IRIZARRY VINCENT A. ROBERTI, SR. ISRAEL S KLEIN